IGM Biosciences, Inc. (IGMS)
NASDAQ: IGMS · IEX Real-Time Price · USD
10.74
+0.03 (0.28%)
At close: Jul 19, 2024, 4:00 PM
10.41
-0.33 (-3.07%)
Pre-market: Jul 22, 2024, 5:11 AM EDT
IGM Biosciences Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for IGM Biosciences stock have an average target of 17, with a low estimate of 8.00 and a high estimate of 25. The average target predicts an increase of 58.29% from the current stock price of 10.74.
Analyst Consensus: Buy
* Price targets were last updated on May 24, 2024.
Analyst Ratings
The average analyst rating for IGMS stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 5 | 5 | 5 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $12 | Hold | Reiterates | $12 | +11.73% | May 24, 2024 |
| Wedbush | Wedbush | Buy Reiterates $20 | Buy | Reiterates | $20 | +86.22% | May 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $12 | Hold | Reiterates | $12 | +11.73% | Apr 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $7 → $12 | Hold | Maintains | $7 → $12 | +11.73% | Mar 12, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $21 | Buy | Reiterates | $21 | +95.53% | Mar 8, 2024 |
Financial Forecast
Revenue This Year
46.70M
from 2.13M
Increased by 2,092.54%
Revenue Next Year
10.63M
from 46.70M
Decreased by -77.23%
EPS This Year
-2.80
from -4.71
EPS Next Year
-3.23
from -2.80
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 66.7M | 41.7M | 134.4M | 465.0M | 649.7M |
| Avg | 46.7M | 10.6M | 51.7M | 224.4M | 359.4M |
| Low | 2.7M | n/a | n/a | 3.9M | 37.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3,030.3% | -10.6% | 1,163.9% | 798.8% | 189.6% |
| Avg | 2,092.5% | -77.2% | 386.5% | 333.7% | 60.2% |
| Low | 26.4% | - | - | -92.4% | -83.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.24 | -2.11 | -1.70 | -2.81 | -2.79 |
| Avg | -2.80 | -3.23 | -2.79 | -2.73 | -2.71 |
| Low | -5.06 | -4.19 | -3.88 | -2.63 | -2.61 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.